Gianluigi Forloni

Key facts

• The Mario Negri Institute department page, retrieved 2026-10-16, names him Capo Dipartimento (head) of the Neuroscience Department, and every recent paper read lists his affiliation as Department of Neuroscience, Mario Negri IRCCS, Milan.
• An editorial board biography seen only as a search excerpt says he has headed the Biology of Neurodegenerative Diseases Lab since 1996 and the Neuroscience Department since 2002, after a biology degree in Milan in 1985 and postdoctoral work at Johns Hopkins; a 2012 blog post gives the same two roles.
• His department hosts the Laboratorio Neurobiologia dei Prioni and lists four prion projects: DOXIFF funded by Fondazione Telethon, ProFFIle funded by the EU Joint Programme Neurodegenerative Disease Research, an anti-prion compound study under Ministry of Health grant RF-2016-02362950, and a CJD Foundation funded study of prion vaccines in transgenic mouse models of familial prion disease.
• The same trial is registered as NCT04846335, first posted only in April 2021: phase 2, sponsor Mario Negri, collaborator Fondazione Telethon, start 28 April 2011, primary completion 12 April 2021, completion 30 November 2024, 29 enrolled, primary outcome survival at ten years, and no results posted.
• He is first author of the 2015 Prion paper that set out the design: doxycycline 100 mg a day for ten years in asymptomatic carriers over 42, judged against historical incidence because a randomised controlled trial was considered ethically unfeasible, with Telethon grant GGP10208.
• He is first author of the 2022 Prion paper on public engagement, written with AFIFF members, Treviso clinicians, Carlo Besta neurologists and a Telethon officer, which explains that genotype stayed blind to participants and lists four Telethon grants (GGP10208, GSP14001, GSP18001, GSP21002).
• He was second author of the phase 2 randomised placebo-controlled doxycycline trial in 121 CJD patients in Italy and France (Lancet Neurology 2014), with Maurizio Pocchiari, Inga Zerr and Fabrizio Tagliavini among co-authors; it found no survival benefit.
• He co-authored the 2024 Nature Reviews Disease Primers overview of CJD and other prion diseases with Inga Zerr, Anna Ladogana, Simon Mead, Peter Hermann and Brian Appleby.
• His 2019 review of prion therapeutic trials argued that sensitive detection of prion aggregates for early biomarkers and immunotherapy research are the openings for prevention.
• In the last 24 months his indexed prion related output is laboratory work on the cellular prion protein as a mediator of tau oligomer toxicity (2025) and a sole author 2025 review of doxycycline in Alzheimer disease; no trial outcome paper was found.

Timeline

1. 2002Head of the Mario Negri Neuroscience Department, per an editorial biography excerpt.
2. 2011Start date of the preventive trial on ClinicalTrials.gov.
3. 2011Italian authorisation of DOXIFF recorded in the EU register.
4. 2014Second author of the Lancet Neurology doxycycline CJD trial.
5. 2015First author of the Prion paper describing the preventive trial design.
6. 2019First author of a review of prion therapeutic trials.
7. 2021Trial first posted on ClinicalTrials.gov.
8. 2022First author of the Prion paper on science and public engagement in the preventive trial.
9. 2024Co-author of the Nature Reviews Disease Primers prion overview.
10. 2024Preventive doxycycline trial in fatal familial insomnia recorded as completed in both registries.
11. 2024Last update posted on ClinicalTrials.gov, still without results.
12. 2025Senior author on tau oligomers acting through the cellular prion protein.
13. 2025Sole author review on doxycycline in Alzheimer disease.
14. 2025Co-author of a Neural Regeneration Research paper on prion protein and tau oligomer synaptotoxicity (issue dated 2026-08).
15. 2026Mario Negri department page retrieved, naming him head of the Neuroscience Department.